Novavax just got an earnings pop

The good news showed up first

Novavax came out swinging with first-quarter sales of $139.5 million, handily topping estimates and giving the stock a nice Wednesday pop. That’s the kind of beat Wall Street likes to see when a company has been living under a microscope.

The loss is still there, but the balance sheet got a little less scary

The company reported a $9 million net loss for the quarter, which is a far cry from the prior year’s headline-grabbing profit, though that comparison was flattered by one-time accounting gains. More importantly, Novavax said it ended the quarter with $795 million in cash, marketable securities, and restricted cash, helped by a $330 million credit facility it lined up in February.

Partnerships, partnerships, partnerships

If you’re looking for Novavax’s big strategy, it’s basically: let the pharma grown-ups do the heavy lifting. Management said it is leaning hard on collaborations with Sanofi and Pfizer to push its Matrix-M technology across vaccines and oncology, and that it has now signed four new Material Transfer Agreements across more than 30 programs.

• More partner-driven revenue expected through 2028
• No need to rely on upfront payments or royalties, according to management
• 2026 sales guidance stayed put at $230 million to $270 million

Why investors care

The market usually forgives a lot when a biotech can show real revenue, a sturdier cash runway, and a plausible story beyond “please believe in the platform.” Novavax did enough on Wednesday to remind traders it’s still in the game, even if the long-term climb looks more like a hiking trail than a red-carpet stroll.

Big picture: this wasn’t a fairy-tale quarter, but it was a credible one — and for NVAX, that’s sometimes enough to get the stock moving.